OREO: A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this clinical trial if you:
- have ovarian, fallopian tube or primary peritoneal cancer of epithelial type. If you have mucinous tumours, you can't take part.
- have a known BRCA 1 or 2 gene mutation status.
- have progression of cancer after having PARP inhibitor maintenance treatment following first-line chemotherapy.
- have recently received platinum-based chemotherapy (carboplatin or cisplatin) and your cancer is responding to treatment.
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
The main purpose of this study is to see if olaparib (study drug) retreatment is effective in participants with ovarian cancer, who have already been treated with olaparib or similar drugs.
The drugs involved in this trial are:
- Olaparib – the drug being tested. This is a tablet taken by mouth
- Placebo – an inactive drug or treatment used in a clinical trial. It's sometimes referred to as a 'sugar pill'.
If you take part in this study, you'll be randomised (placed into a treatment group by a computer) into one of two treatment groups:
- Olaparib
- Placebo
Patients will be randomised in a 2:1 ratio (66 per cent chance of being allocated olaparib versus 33 per cent chance of being allocated placebo).
